Development of Herceptin resistance in breast cancer cells.
about
P1343
Autophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast CancerInsights into HER2 signaling from step-by-step optimization of anti-HER2 antibodiesMultiple Bacteriophage Selection Strategies for Improved Affinity of a Peptide Targeting ERBB2t-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer CellsNeural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.Inferring predominant pathways in cellular models of breast cancer using limited sample proteomic profiling.Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsImmunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic ImplicationsIn situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistanceThe Comparison of The Effects of Silybin and Silybin-Phosphatidylcholine on Viability and ESR Expression in Human Breast Cancer T47D Cell Line.Novel anti-HER2 monoclonal antibodies: synergy and antagonism with tumor necrosis factor-α.Resistance to HER2-targeted therapies: a potential role for FOXM1.Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancerComparing the Effect of Silybin and Silybin Advanced™ on Viability and HER2 Expression on the Human Breast Cancer SKBR3 Cell Line by no Serum Starvation.One target, different effects: a comparison of distinct therapeutic antibodies against the same targets.A mechanistic study of tumor-targeted corrole toxicity.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner.Autophagy Protects from Trastuzumab-Induced Cytotoxicity in HER2 Overexpressing Breast Tumor Spheroids.Chemotherapy targeting by DNA capture in viral protein particlesTreatment of HER2-positive metastatic breast cancer following initial progression.Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells.Induction of caspase-dependent extrinsic apoptosis by apigenin through inhibition of signal transducer and activator of transcription 3 (STAT3) signalling in HER2-overexpressing BT-474 breast cancer cells.Trastuzumab-Resistant Luminal B Breast Cancer Cells Show Basal-Like Cell Growth Features Through NF-κB-ActivationClinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancerNew developments in the treatment of HER2-positive breast cancerImmunotherapeutic strategies to target prognostic and predictive markers of cancer.Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells.Omics and therapy - a basis for precision medicine.Magnetic nanoparticles in MR imaging and drug delivery.Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review.Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.Improving the outcomes: developing cancer therapeutics.Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance.LMO1 is a novel oncogene in lung cancer, and its overexpression is a new predictive marker for anti-EGFR therapy.Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models.Molecular modeling of nearly full-length ErbB2 receptor.
P2860
Q26753162-FDB4F06A-BFBF-43FB-B775-FCAF05568A91Q27683825-15B82341-1AA9-4411-B1F6-CB0FD498C7DCQ28393445-BF7BA45A-7D0A-4936-9511-3C30731408C9Q28545954-3BF7573E-7890-4B91-AA0D-E379DE09557EQ33519052-DCF64DB1-2579-40EF-919F-074DA1D136C8Q33605369-0B2CF0C0-3874-44DE-9416-CC6AC7EF8713Q33644305-10CE07B6-FD78-41A7-8152-95E32C005C22Q33713042-D3B26FAC-3132-4821-ACDC-DADFEB053224Q34223494-619F8BC9-70E7-4BDF-BFA2-59817D57613FQ34334146-0C4066CD-2787-4C08-9C7F-1AF89B3DBB00Q34376252-0D3114A0-EFE1-49E3-B08F-1BCE9E2170EAQ34433064-ADFA755E-472D-47EF-85C6-9DCEBF620818Q34955355-F87720DC-BA64-4ECF-AA55-91C00AADC157Q35229181-BE09C9F9-8DED-4481-916E-968934D1DE6AQ35484007-C6E599C9-4C74-4D06-9566-2F2C31212F6BQ35569418-53BA7114-F571-466C-8B16-B7E6C284478EQ35592635-48297D79-A2D4-4A7A-8CA2-C890B77FD834Q35624814-AD2A78A4-3B99-404D-AF5A-3733D40F571EQ35628811-BDE6C760-4DE2-4851-9FAD-64A84FF3CAD1Q35770542-7B1F052B-364D-4370-8945-274F23C6D1DAQ36194380-8232E332-3878-4523-9D67-D9797E20EFD7Q36275971-F3C358D3-DC12-46C6-BE7B-C9440035737AQ36373337-C3C3D71E-1210-4CBF-888D-6A2EFDEE6A8AQ36450288-CFAD85F4-C3D1-4899-B2C9-6F4BD0FD0231Q36630127-53135126-1FF7-41CF-A8E4-FFE9A27ACC0EQ36643018-1E6C0447-F2CE-4DC0-A863-6A85E933C6A2Q37016382-2EBA1DC2-5F7C-4879-B216-4CF8580297CDQ37126006-02B14207-C9C8-45A6-996F-59BE1A3C93B7Q37165342-5AD936D2-7869-4941-8A8B-5D6D997938FCQ37188017-E38D6BE8-DAAC-4889-B179-2CA1F753A659Q37192908-8CE12373-2E22-42C6-AEE0-7C327B850798Q37360194-B97A5C09-943E-4878-BDFA-B769436DA455Q37385536-9EE92E51-9A40-44F2-B504-73AF96B0952CQ37650735-79AD390F-A4B3-42D6-9CB5-93D43C331AC4Q37965556-4534438A-EBB3-41E9-817A-D6DDA160F955Q38860383-A2CA47EA-AE38-4E87-B683-70A10E301BA3Q38974183-D6AC2C75-F877-4BB3-ADD0-C4D65C9BFB9BQ39109847-8EE30314-F583-4E64-B76D-33FD70F34559Q39630334-F907A3AB-88E8-4B3F-90FF-3ABD9A206185Q40316579-9BEFFB23-8BD2-4BC1-B535-5EC7CF960684
P2860
Development of Herceptin resistance in breast cancer cells.
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Development of Herceptin resistance in breast cancer cells.
@ast
Development of Herceptin resistance in breast cancer cells.
@en
Development of Herceptin resistance in breast cancer cells.
@nl
type
label
Development of Herceptin resistance in breast cancer cells.
@ast
Development of Herceptin resistance in breast cancer cells.
@en
Development of Herceptin resistance in breast cancer cells.
@nl
prefLabel
Development of Herceptin resistance in breast cancer cells.
@ast
Development of Herceptin resistance in breast cancer cells.
@en
Development of Herceptin resistance in breast cancer cells.
@nl
P2093
P356
P1433
P1476
Development of Herceptin resistance in breast cancer cells.
@en
P2093
Bimjhana Bishwokama
Christopher M Lack
Holly Williams
James P Vaughn
Kathy Barrett
Mark Willingham
Tanita Mitchell
Timothy Kute
P356
10.1002/CYTO.A.10095
P4510
P577
2004-02-01T00:00:00Z